Intellia Property Plant Equipment vs Property Plant And Equipment Gross Analysis
NTLA Stock | USD 15.62 0.41 2.70% |
Intellia Therapeutics financial indicator trend analysis is infinitely more than just investigating Intellia Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Intellia Therapeutics is a good investment. Please check the relationship between Intellia Therapeutics Property Plant Equipment and its Property Plant And Equipment Gross accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.
Property Plant Equipment vs Property Plant And Equipment Gross
Property Plant Equipment vs Property Plant And Equipment Gross Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Intellia Therapeutics Property Plant Equipment account and Property Plant And Equipment Gross. At this time, the significance of the direction appears to have strong relationship.
The correlation between Intellia Therapeutics' Property Plant Equipment and Property Plant And Equipment Gross is 0.68. Overlapping area represents the amount of variation of Property Plant Equipment that can explain the historical movement of Property Plant And Equipment Gross in the same time period over historical financial statements of Intellia Therapeutics, assuming nothing else is changed. The correlation between historical values of Intellia Therapeutics' Property Plant Equipment and Property Plant And Equipment Gross is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Property Plant Equipment of Intellia Therapeutics are associated (or correlated) with its Property Plant And Equipment Gross. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant And Equipment Gross has no effect on the direction of Property Plant Equipment i.e., Intellia Therapeutics' Property Plant Equipment and Property Plant And Equipment Gross go up and down completely randomly.
Correlation Coefficient | 0.68 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Property Plant Equipment
Property Plant And Equipment Gross
Most indicators from Intellia Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Intellia Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.At present, Intellia Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 3.37, whereas Issuance Of Capital Stock is forecasted to decline to about 410.5 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 300.9M | 510.3M | 551.6M | 579.1M | Cost Of Revenue | 6.9M | 7.6M | 9.0M | 8.5M |
Intellia Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Intellia Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Intellia Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 334.3M | 676.3M | 1.3B | 1.5B | 1.3B | 686.6M | |
Other Current Liab | 13.3M | 19.9M | 34.2M | 60.9M | 48.4M | 50.8M | |
Total Current Liabilities | 35.6M | 64.3M | 125.8M | 126.6M | 115.2M | 64.2M | |
Total Stockholder Equity | 269.9M | 527.1M | 1.0B | 1.2B | 1.1B | 548.5M | |
Other Liab | 16.1M | 51.4M | 63.5M | 44.0M | 50.6M | 38.1M | |
Net Tangible Assets | 269.9M | 612.1M | 1.2B | 1.4B | 1.6B | 1.7B | |
Property Plant And Equipment Net | 37.1M | 55.1M | 100.1M | 161.0M | 148.1M | 155.5M | |
Net Debt | (38.9M) | (120.7M) | (49.4M) | (392.8M) | (111.4M) | (117.0M) | |
Retained Earnings | (300.9M) | (435.1M) | (703.0M) | (1.2B) | (1.7B) | (1.6B) | |
Accounts Payable | 3.9M | 10.5M | 9.7M | 5.2M | 7.5M | 5.3M | |
Cash | 57.2M | 160.0M | 123.4M | 523.5M | 226.7M | 203.4M | |
Non Current Assets Total | 44.8M | 79.0M | 525.2M | 303.3M | 302.6M | 317.8M | |
Non Currrent Assets Other | 2.9M | 22.0M | 87.7M | 73.0M | 83.9M | 88.1M | |
Other Assets | 2.9M | 4.7M | 4.8M | 15.7M | 18.1M | 19.0M | |
Cash And Short Term Investments | 279.7M | 597.4M | 1.1B | 1.3B | 912.2M | 566.6M | |
Common Stock Shares Outstanding | 47.2M | 56.0M | 70.9M | 77.0M | 88.8M | 50.5M | |
Liabilities And Stockholders Equity | 334.3M | 676.3M | 1.3B | 1.5B | 1.3B | 686.6M | |
Non Current Liabilities Total | 28.8M | 85.0M | 128.4M | 158.0M | 135.6M | 73.9M | |
Other Current Assets | 5.1M | 14.3M | 37.2M | 20.4M | 49.7M | 52.1M | |
Other Stockholder Equity | 570.5M | 962.2M | 1.7B | 2.4B | 2.7B | 2.8B | |
Total Liab | 64.4M | 149.3M | 254.2M | 284.5M | 250.8M | 138.1M | |
Property Plant And Equipment Gross | 37.1M | 55.1M | 126.2M | 194.2M | 188.0M | 197.4M | |
Total Current Assets | 289.5M | 597.4M | 769.3M | 1.2B | 998.3M | 541.2M | |
Accumulated Other Comprehensive Income | 261K | 1K | (2.6M) | (7.5M) | (2.3M) | (2.4M) | |
Property Plant Equipment | 37.1M | 15.9M | 21.0M | 27.9M | 32.1M | 18.1M | |
Current Deferred Revenue | 12.7M | 22.5M | 63.8M | 43.8M | 22.1M | 29.3M | |
Net Receivables | 4.6M | 2.1M | 2.0M | 3.8M | 36.5M | 38.3M | |
Capital Surpluse | 570.5M | 962.2M | 1.7B | 2.4B | 2.8B | 2.9B | |
Retained Earnings Total Equity | (300.9M) | (435.1M) | (703.0M) | (1.2B) | (1.1B) | (1.0B) | |
Short Term Investments | 222.5M | 437.4M | 625.3M | 669.1M | 685.5M | 398.1M | |
Net Invested Capital | 269.9M | 527.1M | 1.0B | 1.2B | 1.1B | 738.8M | |
Net Working Capital | 253.8M | 552.3M | 643.5M | 1.1B | 883.1M | 633.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Intellia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intellia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intellia Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intellia Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Intellia Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.45) | Revenue Per Share 0.449 | Quarterly Revenue Growth (0.24) | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.